Shares of Valneva (VALN), a specialty vaccine company closed up over $1.00 per share or almost 19% to close the regular session at $6.67 per share after announcing the Medicines and Healthcare products Regulatory Agency or MHRA had granted marketing authorization in the United Kingdom “for the world’s first and only chikungunya vaccine, IXCHIQ.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VALN:
- MHRA grants Valneva marketing authorization for chikungunya vaccine
- Valneva’s Chikungunya Vaccine Gains UK Approval, Expanding Global Reach
- Valneva Secures New $32.8 Million Contract for IXIARO® with U.S. Department of Defense
- Valneva Reports Positive Trial Results for Pediatric Chikungunya Vaccine
- Valneva reports Phase 2 results in children for its chikungunya vaccine